Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:4053065rdf:typepubmed:Citationlld:pubmed
pubmed-article:4053065lifeskim:mentionsumls-concept:C0684336lld:lifeskim
pubmed-article:4053065lifeskim:mentionsumls-concept:C0080103lld:lifeskim
pubmed-article:4053065lifeskim:mentionsumls-concept:C0031327lld:lifeskim
pubmed-article:4053065lifeskim:mentionsumls-concept:C0232804lld:lifeskim
pubmed-article:4053065lifeskim:mentionsumls-concept:C0600688lld:lifeskim
pubmed-article:4053065lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:4053065lifeskim:mentionsumls-concept:C0057856lld:lifeskim
pubmed-article:4053065pubmed:issue11 Pt 2lld:pubmed
pubmed-article:4053065pubmed:dateCreated1985-11-29lld:pubmed
pubmed-article:4053065pubmed:abstractTextThe pharmacokinetics of iproplatin, a quadrivalent second-generation platinum complex the dose-limiting toxicity of which is myelosuppression, was studied in patients with different degrees of renal function impairment. The drug was administered in a 30-min i.v. infusion. The plasma decay of iproplatin was biphasic, with an overall median terminal phase half-life of 3.16 +/- 2.6 (SD) h. The overall mean volume of distribution (Vss) was 39.9 +/- 25.0 liters, with a total body clearance of 14.25 +/- 3.99 liters/h. The total body clearance of iproplatin showed a linear correlation, with renal function measured as creatinine clearance. The toxicity of the drug, expressed as percentage of reduction in platelet count, correlated linearly with the area under the concentration X time curve.lld:pubmed
pubmed-article:4053065pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:4053065pubmed:languageenglld:pubmed
pubmed-article:4053065pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:4053065pubmed:citationSubsetIMlld:pubmed
pubmed-article:4053065pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:4053065pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:4053065pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:4053065pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:4053065pubmed:statusMEDLINElld:pubmed
pubmed-article:4053065pubmed:monthNovlld:pubmed
pubmed-article:4053065pubmed:issn0008-5472lld:pubmed
pubmed-article:4053065pubmed:authorpubmed-author:CreavenP JPJlld:pubmed
pubmed-article:4053065pubmed:authorpubmed-author:MadajewiczSSlld:pubmed
pubmed-article:4053065pubmed:authorpubmed-author:PendyalaLLlld:pubmed
pubmed-article:4053065pubmed:issnTypePrintlld:pubmed
pubmed-article:4053065pubmed:volume45lld:pubmed
pubmed-article:4053065pubmed:ownerNLMlld:pubmed
pubmed-article:4053065pubmed:authorsCompleteYlld:pubmed
pubmed-article:4053065pubmed:pagination5936-8lld:pubmed
pubmed-article:4053065pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:4053065pubmed:meshHeadingpubmed-meshheading:4053065-...lld:pubmed
pubmed-article:4053065pubmed:meshHeadingpubmed-meshheading:4053065-...lld:pubmed
pubmed-article:4053065pubmed:meshHeadingpubmed-meshheading:4053065-...lld:pubmed
pubmed-article:4053065pubmed:meshHeadingpubmed-meshheading:4053065-...lld:pubmed
pubmed-article:4053065pubmed:meshHeadingpubmed-meshheading:4053065-...lld:pubmed
pubmed-article:4053065pubmed:meshHeadingpubmed-meshheading:4053065-...lld:pubmed
pubmed-article:4053065pubmed:meshHeadingpubmed-meshheading:4053065-...lld:pubmed
pubmed-article:4053065pubmed:year1985lld:pubmed
pubmed-article:4053065pubmed:articleTitleEffect of renal function impairment of iproplatin pharmacokinetics and relation to toxicity.lld:pubmed
pubmed-article:4053065pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:4053065pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:4053065pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed